JP7811843B2 - 微生物生着のための方法および組成物 - Google Patents

微生物生着のための方法および組成物

Info

Publication number
JP7811843B2
JP7811843B2 JP2021502898A JP2021502898A JP7811843B2 JP 7811843 B2 JP7811843 B2 JP 7811843B2 JP 2021502898 A JP2021502898 A JP 2021502898A JP 2021502898 A JP2021502898 A JP 2021502898A JP 7811843 B2 JP7811843 B2 JP 7811843B2
Authority
JP
Japan
Prior art keywords
composition
microorganism
rrna
microorganisms
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532097A (ja
JP2021532097A5 (https=
JPWO2020018949A5 (https=
Inventor
ジョン エス． イード，
コリーン カットクリフ，
ジェイムズ エイチ． バラード，
ニコラス ジャスティス，
ジェシカ ジーネス，
スラビ チャギ，
マーカス エフ． シクルバーガー，
アンドリュー ティー． チェン，
ポール マクマーディー，
クリスチャン ジーバー，
Original Assignee
ペンデュラム セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペンデュラム セラピューティクス， インコーポレイテッド filed Critical ペンデュラム セラピューティクス， インコーポレイテッド
Publication of JP2021532097A publication Critical patent/JP2021532097A/ja
Publication of JP2021532097A5 publication Critical patent/JP2021532097A5/ja
Publication of JPWO2020018949A5 publication Critical patent/JPWO2020018949A5/ja
Priority to JP2024056157A priority Critical patent/JP2024074864A/ja
Application granted granted Critical
Publication of JP7811843B2 publication Critical patent/JP7811843B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021502898A 2018-07-19 2019-07-19 微生物生着のための方法および組成物 Active JP7811843B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024056157A JP2024074864A (ja) 2018-07-19 2024-03-29 微生物生着のための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862700682P 2018-07-19 2018-07-19
US62/700,682 2018-07-19
PCT/US2019/042670 WO2020018949A2 (en) 2018-07-19 2019-07-19 Methods and compositions for microbial engraftment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024056157A Division JP2024074864A (ja) 2018-07-19 2024-03-29 微生物生着のための方法および組成物

Publications (4)

Publication Number Publication Date
JP2021532097A JP2021532097A (ja) 2021-11-25
JP2021532097A5 JP2021532097A5 (https=) 2022-07-26
JPWO2020018949A5 JPWO2020018949A5 (https=) 2022-07-26
JP7811843B2 true JP7811843B2 (ja) 2026-02-06

Family

ID=69163794

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502898A Active JP7811843B2 (ja) 2018-07-19 2019-07-19 微生物生着のための方法および組成物
JP2024056157A Pending JP2024074864A (ja) 2018-07-19 2024-03-29 微生物生着のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024056157A Pending JP2024074864A (ja) 2018-07-19 2024-03-29 微生物生着のための方法および組成物

Country Status (7)

Country Link
US (1) US12343360B2 (https=)
EP (1) EP3823651A4 (https=)
JP (2) JP7811843B2 (https=)
CN (1) CN113164526A (https=)
AU (1) AU2019306649A1 (https=)
CA (1) CA3106315A1 (https=)
WO (1) WO2020018949A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3106315A1 (en) * 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
JP2023165053A (ja) * 2020-10-07 2023-11-15 国立大学法人東京農工大学 治療用組成物、治療方法、糞便の評価方法、診断方法、及び予後評価方法
KR102880991B1 (ko) * 2021-12-17 2025-11-03 박선민 뮤신 분해능을 갖는 혼합 균주 및 그의 용도
CN115960999A (zh) * 2022-12-16 2023-04-14 暨南大学 一套用于筛选高抗炎活性β葡聚糖的生物标志物及其应用
CN118955187B (zh) * 2024-08-01 2025-07-15 江西农业大学 一种多糖基肥料在重金属胁迫条件下提高植物根部机械强度及抗倒伏性能上的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017134240A1 (en) 2016-02-04 2017-08-10 Universiteit Gent Use of microbial communities for human and animal health
WO2017146580A1 (en) 2016-02-25 2017-08-31 Caelus Pharmaceuticals B.V. Compositions and methods for preventing and/or treating vitamin b12 deficiency
JP2017535597A (ja) 2014-10-31 2017-11-30 ホール バイオーム インコーポレイテッド 障害の微生物的処置および診断に関する方法および組成物
JP2018502926A (ja) 2015-01-26 2018-02-01 カレイド・バイオサイエンシズ・インコーポレイテッド グリカン治療剤及びその関連方法
WO2018106844A1 (en) 2016-12-06 2018-06-14 Whole Biome Inc. Methods and compositions relating to isolated and purified microbes

Family Cites Families (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5143845A (en) 1986-09-03 1992-09-01 Toa Pharmaceutical Co., Ltd. Mixture of saccarifying lactic acid producing and butyric acid producing bacteria
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
EP0433299B1 (en) 1988-08-02 1998-05-06 Gastro Services Pty. Limited (ACN 002 994 890) Treatment of gastro-intestinal disorders
JP2961182B2 (ja) 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
EP0678034B1 (en) 1993-01-11 1999-05-26 Dana Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
GB9306473D0 (en) 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
JPH08298982A (ja) 1995-05-02 1996-11-19 Aasu Giken:Kk 複合微生物製剤
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
PL347058A1 (en) 1998-09-17 2002-03-11 North American Vaccine Streptococcal c beta protein compositions
EP1137423B1 (en) 1998-12-11 2005-03-09 Urex Biotech, Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
DE60041770D1 (de) 1999-08-05 2009-04-23 Nestle Sa Bifidobacteria zum vorbeugen von diarrhöe infolge pathogener bakterien
JP4580542B2 (ja) 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
DE10043151A1 (de) 2000-08-31 2002-03-28 Peter Steinruecke Knochenzement mit antimikrobieller Wirksamkeit
EP1227152A1 (en) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
KR100845456B1 (ko) 2001-02-06 2008-07-10 소시에떼 데 프로듀이 네슬레 소시에떼아노님 젖산균 및 비피도균에 의한 내독소 결합
WO2002085415A1 (en) 2001-04-17 2002-10-31 Biomatrix, Inc Non-digestible sugar-coated products and process
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
MXPA04008177A (es) 2002-02-21 2005-06-08 Nestle Sa Composicion oralmente administrable, para la fotoproteccion de la piel.
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
SE526711C2 (sv) 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
WO2004101770A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1462116A1 (en) 2003-03-29 2004-09-29 Villitech SARL Composition for treating the gastrointestinal tract
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20050100559A1 (en) 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
MXPA06015184A (es) 2004-06-23 2007-11-22 Nestec Sa Procedimiento y composiciones utiles para prevenir y/o tratar pieles sensibles y/o secas.
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20041550A1 (it) 2004-07-29 2004-10-29 Proge Farm Srl Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
FR2874825B1 (fr) 2004-09-08 2006-12-08 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
PT1835021E (pt) 2004-12-28 2011-04-29 Meiji Seika Kaisha Nova estirpe que confere a um hospedeiro propriedades anti-doença e composição de células bacterianas
TW200700074A (en) 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
US20060223153A1 (en) 2005-04-05 2006-10-05 Luca Technologies, Llc Generation of materials with enhanced hydrogen content from anaerobic microbial consortia
WO2006119052A2 (en) 2005-05-03 2006-11-09 Anaerobe Systems Anaerobic production of hydrogen and other chemical products
JP2006314219A (ja) 2005-05-11 2006-11-24 Asahi Breweries Ltd 腸内細菌を利用した胆汁酸の吸着方法、および胆汁酸吸着物質
JP2007031291A (ja) 2005-07-22 2007-02-08 Ace Bio Product Kk 体重増加抑制剤及び体重増加抑制飲料
FR2889958A1 (fr) 2005-08-25 2007-03-02 Lyoct Sa Lab Utilisation d'un symbiotique pour le traitement de la dermatite atopique
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
WO2007085970A2 (en) 2006-01-27 2007-08-02 Danisco A/S Use of probiotic microorganisms for the treatment and prevention of obesity and related disorders
ITRM20060237A1 (it) 2006-05-03 2007-11-04 Anabasis S R L Uso dei probiotici nella prevenzione e nel trattamento delle congiuntiviti allergiche
EP2040724B1 (en) 2006-05-18 2011-10-05 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and metronidazole and uses thereof
JP5019563B2 (ja) 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
CN101095698B (zh) 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
EP2102350A4 (en) 2006-12-18 2012-08-08 Univ St Louis DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES
AU2007347318A1 (en) 2007-02-22 2008-08-28 Jurgen Schrezenmeir Probiotic, gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in humans
US9644210B2 (en) 2007-02-22 2017-05-09 Jürgen Schrezenmeir Probiotic gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in human
BRPI0809448A2 (pt) 2007-03-28 2014-09-09 Alimentary Health Ltd Cepas de bifidobacterium probióticas
CA2682242A1 (en) 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic bifidobacterium longum strain
JP5536640B2 (ja) 2007-05-03 2014-07-02 オロフソン、トビアス 新鮮な蜂蜜又はミツバチの蜂蜜産生管から単離された新規細菌
TW200904340A (en) 2007-05-11 2009-02-01 Mannatech Inc Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
ES2578261T3 (es) 2007-05-18 2016-07-22 Nestec S.A. Lactobacillus johnsonii para prevenir infecciones postoperatorias
US20090010892A1 (en) 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Hyperlipidemia Treatment Agent
US20090010891A1 (en) 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Sepsis Treatment Agent
WO2009018447A2 (en) 2007-07-31 2009-02-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
US20100284979A1 (en) 2007-10-01 2010-11-11 University College Cork, National University Of Ireland, Cork Modulation of Tissue Fatty Acid Composition of a Host by Human Gut Bacteria
US8478544B2 (en) 2007-11-21 2013-07-02 Cosmosid Inc. Direct identification and measurement of relative populations of microorganisms with direct DNA sequencing and probabilistic methods
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
ES2343499B1 (es) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
US20110189149A1 (en) 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
CN102089422B (zh) 2008-07-11 2013-07-17 科.汉森有限公司 新的益生长双歧杆菌
US8569466B2 (en) 2008-09-10 2013-10-29 Nnochiri Ekwuribe Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers
EP2337569A4 (en) 2008-09-25 2013-04-03 Univ New York COMPOSITIONS AND METHODS FOR CHARACTERIZING AND RESTORING THE STOMACH DARM, SKIN AND NOSE MICROBIOTA
WO2010040055A2 (en) 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
MX356598B (es) 2008-11-11 2018-06-04 Alimentary Health Ltd Bifidobacterium longum.
JP5606672B2 (ja) 2008-11-26 2014-10-15 太陽化学株式会社 シンバイオティクスを利用した腸内環境調整方法
WO2010096550A2 (en) 2009-02-18 2010-08-26 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
SG173832A1 (en) 2009-02-24 2011-09-29 Ritter Pharmaceuticals Inc Prebiotic formulations and methods of use
US20100086981A1 (en) 2009-06-29 2010-04-08 Qteros, Inc. Compositions and methods for improved saccharification of biomass
DK2411027T3 (en) 2009-03-25 2015-01-19 Chr Hansen As USING a probiotic ADJUSTING body weight
US20120027737A1 (en) 2009-03-25 2012-02-02 Chr-Hansen A/S Use of probiotics to ameliorate diet-induced insulin resistance
BRPI1014800A8 (pt) 2009-05-07 2016-10-11 Tate & Lyle Ingredients France SAS "composição compreendendo alfa-(1,6) oligodextranas alfa-(1,2) ramificadas, método para preparar as referidas oligodextranas e uso das mesmas"
US8784798B2 (en) 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
US20150320808A1 (en) 2009-06-19 2015-11-12 Dupont Nutrition Biosciences Aps Bifidobacteria for treating cardiac conditions
EP3181134B1 (en) 2009-06-19 2019-10-30 DuPont Nutrition Biosciences ApS Bifidobacteria for treating diabetes and related conditions
US9848760B2 (en) 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
US20120129794A1 (en) 2009-07-24 2012-05-24 Dowd Scot E Apparati, methods, and compositions for universal microbial diagnosis, detection, quantification, and specimen-targeted therapy
EP2459203B1 (en) 2009-07-30 2018-10-31 DuPont Nutrition Biosciences ApS Lactic acid bacteria and bifidobacteria for treating endotoxemia
TR201807143T4 (tr) 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
CA2776420A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
BR112012011294B1 (pt) 2009-11-12 2018-03-20 Nestec S.A. Composição nutricional para administração a um indivíduo
DK2513292T3 (da) 2009-12-16 2017-11-13 Probiotical Spa Konjugeret linolsyre-producerende stammer af probiotiske bakterier og anvendelse deraf til fremstillingen af en farmaceutisk sammensætning
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
US20120301450A1 (en) 2010-02-10 2012-11-29 Hirokuni Miyamoto Mixture, dissolving solution and pharmaceutical agent each comprising thermophilic microorganism
CN102939391A (zh) 2010-03-01 2013-02-20 国家农艺研究院 炎症性肠病的诊断方法
AU2011223002B2 (en) 2010-03-01 2015-07-02 Institut National De La Recherche Agronomique Method of diagnostic of obesity
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
EP2563372A4 (en) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc PREBIOTIC FORMULATIONS AND METHODS OF USE
FI20105478A0 (fi) 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
EP2586448B1 (en) 2010-06-28 2018-02-07 Kabushiki Kaisha Yakult Honsha Skin properties improving agent for oral administration
ES2744576T3 (es) 2010-06-30 2020-02-25 Nestle Sa Uso de ácido cicórico y bacteria láctica en suplemento alimenticio para aclarar y/o blanquear el tono de la piel
US20130143288A1 (en) 2010-08-12 2013-06-06 The Administrators Of The Tulane Educational Fund Isolated bacteria, methods for use, and methods for isolation
WO2012024638A2 (en) 2010-08-20 2012-02-23 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
CA2811056A1 (en) 2010-09-10 2012-03-15 Viropharma Incorporated Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use
DK2439264T3 (en) 2010-10-11 2015-08-03 Jennewein Biotechnologie Gmbh Novel fucosyltransferases and their use
US20120165792A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
BR112013017023A2 (pt) 2010-12-29 2019-09-24 Nestec Sa fibra e probióticos para a redução dos sintomas instestinais relacionados com o estresse
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
JP2014506923A (ja) 2011-03-01 2014-03-20 クオラム イノベーションズ リミテッド ライアビリティ カンパニー 病原性バイオフィルムと関連した状態を治療するための物質および方法
MX2013010343A (es) 2011-03-09 2014-04-30 Univ Minnesota Composicion y metodos para el transplante de microbiota de colon.
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
JP5877902B2 (ja) 2011-08-17 2016-03-08 マイクロバイオーム セラピューティクス，エルエルシー バクテロイデス門の胃腸管微生物相対フィルミクテス門の微生物相の比を上昇させるための組成物および製剤の使用
EP2744888B1 (en) 2011-08-18 2017-12-13 Chr. Hansen A/S Method for purifying bacterial cells
SG11201401811WA (en) 2011-08-30 2014-09-26 Amc Amsterdam Method for preventing and/or treating insulin resistance
ES2662793T3 (es) 2011-09-14 2018-04-09 Nubiyota Llc Complementos de medio y métodos para cultivar microorganismos anaerobios gastrointestinales humanos
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
FI20116008A0 (fi) 2011-10-12 2011-10-12 Maeyrae Maekinen Annika Viskeraalisen rasvan estäminen ja diagnostisointi
WO2013067185A1 (en) 2011-11-02 2013-05-10 Bios Llc Probiotic stick formulation for skin maintenance and methods of use
BR112014010660A2 (pt) 2011-11-04 2017-05-09 Gen Mills Inc métodos e composições para modular bactéria gastrointestinal
CN103131647B (zh) * 2011-11-29 2017-06-27 上海上药信谊药厂有限公司 婴儿双歧杆菌及其制剂
CN116942833A (zh) 2011-12-01 2023-10-27 国立大学法人 东京大学 诱导调节性t细胞的增殖或积累的人源细菌
SG10201609078TA (en) 2011-12-07 2016-12-29 Asahi Group Holdings Ltd Lipid Metabolism And/Or Sugar Metabolism Improver Containing Lactic Acid Bacterium Or Treatment Product Thereof
WO2013107913A1 (en) 2012-01-19 2013-07-25 University College Cork - National University Of Ireland, Cork Gaba-producing culturable bacteria derived from the human gastrointestinal tract
IN2014DN07752A (https=) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
US20130344042A1 (en) 2012-06-20 2013-12-26 Gretchen Tanbonliong Dietary management of celiac disease and food allergy
WO2014011233A1 (en) 2012-07-09 2014-01-16 Trachtman Ira Milton Compositions and method for treatment and prophylaxis of inflammatory bowel disease
US10093894B2 (en) 2012-08-20 2018-10-09 Chr. Hansen A/S Method for optimizing a process for freeze drying a bacteria-containing concentrate
DK2898061T3 (da) 2012-09-20 2020-02-10 Prothera Inc Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
EP2914135A1 (en) 2012-11-01 2015-09-09 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
EP3967315B1 (en) 2012-11-19 2025-05-14 Université catholique de Louvain Akkermansia muciniphila for treating cancer
CA3212215A1 (en) 2012-11-23 2014-05-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2014088982A1 (en) 2012-12-07 2014-06-12 Albert Einstein College Of Medicine Of Yeshiva University Gut barrier dysfunction treatment and prevention
HK1218560A1 (zh) 2013-02-04 2017-02-24 Seres Therapeutics, Inc. 组成与方法
CA2899925A1 (en) 2013-02-04 2014-08-07 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
CN105228635A (zh) 2013-03-05 2016-01-06 格罗宁根大学 Faecalibacterium prausnitzii HTF-F（DSM 26943）在抑制炎症中的应用
US20160040215A1 (en) 2013-03-14 2016-02-11 Seres Therapeutics, Inc. Methods for Pathogen Detection and Enrichment from Materials and Compositions
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
US10716802B2 (en) 2013-03-15 2020-07-21 The Brigham And Women's Hospital, Inc. Compounds to modulate intestinal absorption of nutrients
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
US20160120915A1 (en) 2013-06-10 2016-05-05 New York University Methods for manipulating immune responses by altering microbiota
KR101470513B1 (ko) 2013-07-17 2014-12-08 주식회사 아모그린텍 대전류 직류중첩특성 및 코어손실 특성이 우수한 연자성 코어 및 그의 제조방법
JP6637885B2 (ja) 2013-07-21 2020-01-29 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
AU2014331610B2 (en) 2013-10-03 2019-11-07 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof
US10058576B2 (en) 2013-10-03 2018-08-28 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
EP3060656A1 (en) 2013-10-24 2016-08-31 Yeda Research and Development Co., Ltd. Polynucleotides encoding brex system polypeptides and methods of using same
GB201319539D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319540D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319525D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319531D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319538D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
EP3074027B1 (en) 2013-11-25 2024-12-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR20150066772A (ko) 2013-12-09 2015-06-17 주식회사 쎌바이오텍 신규한 유산균 및 이를 포함하는 영유아의 설사병 예방 또는 치료용 조성물
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
EP3082777A4 (en) 2013-12-20 2017-06-21 9286-3620 Québec Inc. Protein-based enteric coating for oral dosage forms
CA2930348C (en) 2013-12-20 2023-03-07 Nestec S.A. Nutritional compositions for reducing intestinal pathogens
EP3102670A4 (en) 2014-02-04 2017-07-12 Micro-nature LLC Systems, methods, and compositions relating to combiomics
WO2015120471A1 (en) 2014-02-10 2015-08-13 The Johns Hopkins University Devices for and methods of treatment of metabolic syndromes
US20160354418A1 (en) 2014-02-14 2016-12-08 Vesale Pharma Sa Use of compositions comprising bifidobacterium animalis ssp. lactis lmg p-28149
WO2015131076A1 (en) 2014-02-27 2015-09-03 Yale University Nlrp6 inflammasome intestinal epithelium mucus secretion
US20150246081A1 (en) 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
US20150374760A1 (en) 2014-04-09 2015-12-31 Jose U. Scher Methods for treating psoriasis and psoriatic arthritis
EP3058085B1 (en) 2014-04-28 2021-02-17 Yeda Research and Development Co., Ltd. Microbiome response to agents
CN111768837A (zh) 2014-04-28 2020-10-13 耶达研究及发展有限公司 用于预测对食物的反应的方法和装置
FI127483B (en) 2014-06-11 2018-07-13 Gut Guide Oy Microbial marker for celiac disease and related product
MX2014009044A (es) 2014-07-25 2016-01-25 Polioles S A De C V Nuevas moléculas derivadas de 2-fenil-imidazolinas fosforiladas, con alta estabilidad del anillo imidazolina y alta efectividad como inhibidores de corrosión.
RU2699981C2 (ru) 2014-08-18 2019-09-11 Сосьете Де Продюи Нестле С.А. Пребиотики для снижения риска развития ожирения в дальнейшей жизни
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
EP3209308B1 (en) 2014-10-24 2022-08-03 Evolve Biosystems Inc. Activated bifidobacteria and methods of use thereof
EP3212191B1 (en) 2014-10-28 2022-10-05 Medlab IP Pty Ltd. Treatment for depression and depressive disorders
JP2017533723A (ja) 2014-11-17 2017-11-16 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． マイクロバイオーム解析方法
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
BR112017010475A2 (pt) 2014-11-26 2018-04-03 Probiotical Spa cepas de lactobacillus ou bifidobacterium para manter homeostase
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
CN107405369A (zh) 2015-01-09 2017-11-28 瓦赫宁根大学 包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法
CN107405321A (zh) 2015-01-23 2017-11-28 坦普尔大学 短链脂肪酸在癌症预防中的应用
WO2016139217A1 (en) 2015-03-04 2016-09-09 Ab-Biotics, S.A. Composition comprising anaerobically cultivated human intestinal microbiota
CA2979529A1 (en) 2015-03-13 2016-09-22 Evolve Biosystems, Inc. Compositions that metabolize or sequester free sugar monomers and uses thereof
US20160271189A1 (en) 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
EP3289093A4 (en) 2015-04-28 2019-04-17 Yeda Research and Development Co., Ltd. USE OF MICROBIAL METABOLITES FOR THE TREATMENT OF DISEASES
WO2016176380A1 (en) 2015-04-28 2016-11-03 The Procter & Gamble Company Compositions comprising whole, non-viable micrococcus for improving skin health
MX383750B (es) 2015-05-06 2025-03-14 Univ Wageningen Método para el cultivo de akkermansia
PL3292135T3 (pl) 2015-05-06 2023-01-02 Wageningen Universiteit Zastosowanie polipeptydu do wpływania na sygnalizację odpornościową i/lub wpływania na funkcję bariery jelitowej i/lub modulowania stanu metabolicznego
KR101589466B1 (ko) 2015-05-21 2016-02-01 주식회사 쎌바이오텍 성장 촉진을 위한 비피도박테리움 롱굼 cbt bg7 균주 및 이를 포함하는 성장촉진용 기능성 식품 조성물
BR112017024928A2 (pt) 2015-05-21 2018-07-31 Yeda Research And Development Co Ltd Métodos para prevenção da diabetes ou pré- diabetes em um indivíduo, para melhoria da resposta à glicose em um indivíduo com intolerância à glicose, para manutenção da resposta à glicose em um indivíduo com tolerância à glicose e para melhoria da saúde de um indivíduo, composição probiótica e composição farmacêutica
KR101589464B1 (ko) 2015-05-21 2016-02-01 주식회사 쎌바이오텍 신규한 비피더스 균주 및 이를 포함하는 성장촉진용 기능성 식품 조성물
WO2016194427A1 (ja) 2015-05-30 2016-12-08 日環科学株式会社 プロバイオティクス、あるいはプレバイオティクス、並びにその製造方法、微生物製剤、健康食品並びに医薬品
EP3915552A1 (en) 2015-06-01 2021-12-01 Xeno Biosciences Inc. Compositions for use in modulating the gut microbiota and managing weight
US20160355847A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Of Agriculture Novel Clostridium Species That Converts Wheat Straw and Switchgrass Hydrolysates Into Butyric Acid
US20180153944A1 (en) 2015-06-09 2018-06-07 Regents Of The University Of Minnesota Methods for detecting risk of having a bloodstream infection and compositions for reducing the risk
GB201514303D0 (en) 2015-07-16 2015-09-23 Dupont Nutrition Biosci Aps Bifidobacteria for treating cardiac conditions
JP6889699B2 (ja) 2015-07-29 2021-06-18 アドバンスド バイオニュートリション コープ． 特定栄養用途のための安定乾燥プロバイオティクス組成物
WO2017024237A1 (en) 2015-08-06 2017-02-09 The Johns Hopkins University Composition and method for treatment of metabolic disorders
US10300043B2 (en) 2015-08-12 2019-05-28 Mayo Foundation For Medical Education And Research Method for treating a gastrointestinal disorder in a mammal using bacteroides thetaiotaomicron and compositions thereof
CN105030841A (zh) 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
CN105106245A (zh) 2015-08-24 2015-12-02 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
CN108289917A (zh) 2015-08-24 2018-07-17 努比约塔有限公司 使用粪源细菌群落来治疗微生态失衡的系统和方法
AU2016311452A1 (en) 2015-08-25 2018-02-22 Kaleido Biosciences, Inc. Glycan compositions and uses thereof
WO2017032897A1 (en) 2015-08-27 2017-03-02 Alimentary Health Limited Use of bifidobacterium longum and an exopolysaccharide produced thereby
MX2018001820A (es) 2015-08-27 2018-05-17 Procter & Gamble Bifidobacterium longum.
CA2997100C (en) 2015-09-04 2024-10-29 Memorial Sloan-Kettering Cancer Center METHODS AND COMPOSITIONS FOR DETECTING THE RISK OF CANCER RELAPSE
PT3626081T (pt) 2015-09-10 2022-02-25 Univ Catholique Louvain Akkermansia pasteurizada para promover a perda de peso
WO2017047968A1 (ko) 2015-09-15 2017-03-23 경희대학교 산학협력단 다양한 기능성을 가진 신규 유산균 및 이의 용도
US10537597B2 (en) 2015-10-05 2020-01-21 Schweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In Davos Use of Akkermansia muciniphila for treating inflammatory conditions
US11235010B2 (en) 2015-10-07 2022-02-01 Galderma Research & Development Composition containing lactic acid bacteria and its use to treat atopic dermatitis
US20180311144A1 (en) 2015-10-15 2018-11-01 Natura Cosméticos S.A. Cosmetic composition having probiotic bacteria
BR112018008358A2 (pt) 2015-10-26 2019-04-24 Crestovo Holdings Llc ?composições e métodos para terapia relacionada à microbiota fecal?
CN115252650A (zh) 2015-11-03 2022-11-01 布里格姆及妇女医院股份有限公司 用于治疗和/或预防食物变态反应的治疗性微生物群
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US20190247447A1 (en) 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
US9668991B1 (en) 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
MX378890B (es) 2015-12-11 2025-03-10 Alimentary Health Ltd Bifidobacterium longum ncimb 41715 para usarse en el tratamiento de obesidad y trastornos metabólicos asociados.
CN109069548A (zh) 2015-12-14 2018-12-21 麦太宝根有限公司 肝内胆汁淤积及相关肝疾病的治疗
WO2017105990A1 (en) 2015-12-14 2017-06-22 Massachusetts Institute Of Technology Ph-responsive mucoadhesive polymeric encapsulated microorganisms
JPWO2017130859A1 (ja) 2016-01-28 2018-11-15 森永乳業株式会社 神経細胞死抑制剤
CN109069522A (zh) * 2016-03-14 2018-12-21 物产食品科技股份有限公司 肠内丁酸增加剂及丁酸产生菌增殖剂
US20180357375A1 (en) 2017-04-04 2018-12-13 Whole Biome Inc. Methods and compositions for determining metabolic maps
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
CN111372596A (zh) * 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
JP2021501185A (ja) * 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
WO2019178542A1 (en) 2018-03-16 2019-09-19 Persephone Biome, Inc. Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same
CA3106315A1 (en) * 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
CA3113684A1 (en) * 2018-09-24 2020-04-02 Pendulum Therapeutics, Inc. Microbial compositions and methods of use
KR102197180B1 (ko) 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
SG11202112515RA (en) 2019-05-21 2021-12-30 Pendulum Therapeutics Inc Methods and compositions for treating liver disorders
KR102128287B1 (ko) 2019-08-23 2020-06-30 주식회사 엔테로바이옴 아커만시아 뮤시니필라 eb-amdk19 균주 및 그의 용도
EP4058031A4 (en) 2019-11-14 2023-11-08 Glycom A/S SYNTHETIC COMPOSITION FOR BALANCING THE BALE ACID PROFILE IN THE INTESTINAL
WO2022271729A1 (en) * 2021-06-21 2022-12-29 Pendulum Therapeutics, Inc. Compositions comprising microbes and methods of use and making thereof
CN117957007A (zh) 2021-07-20 2024-04-30 鲁汶大学 奖励失调病症的预防和/或治疗
BE1029496B1 (fr) 2021-08-19 2023-01-16 The Akkermansia Company Composition comprenant de l'Akkermansia muciniphila pasteurisée pour le traitement ou la prévention des troubles de la contractilité intestinale, en particulier des troubles de l'amplitude de la contractilité duodénale
US20250195586A1 (en) 2022-03-15 2025-06-19 Pendulum Therapeutics, Inc. Novel Microbial Composition and Methods of Use Thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535597A (ja) 2014-10-31 2017-11-30 ホール バイオーム インコーポレイテッド 障害の微生物的処置および診断に関する方法および組成物
JP2018502926A (ja) 2015-01-26 2018-02-01 カレイド・バイオサイエンシズ・インコーポレイテッド グリカン治療剤及びその関連方法
WO2017134240A1 (en) 2016-02-04 2017-08-10 Universiteit Gent Use of microbial communities for human and animal health
WO2017146580A1 (en) 2016-02-25 2017-08-31 Caelus Pharmaceuticals B.V. Compositions and methods for preventing and/or treating vitamin b12 deficiency
WO2018106844A1 (en) 2016-12-06 2018-06-14 Whole Biome Inc. Methods and compositions relating to isolated and purified microbes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
mBIO, 2017年, Vol.8, No.5, e00770-17, pp.1-14

Also Published As

Publication number Publication date
CN113164526A (zh) 2021-07-23
WO2020018949A2 (en) 2020-01-23
JP2024074864A (ja) 2024-05-31
AU2019306649A1 (en) 2021-02-04
EP3823651A2 (en) 2021-05-26
WO2020018949A3 (en) 2020-02-27
US20210205374A1 (en) 2021-07-08
CA3106315A1 (en) 2020-01-23
US12343360B2 (en) 2025-07-01
EP3823651A4 (en) 2022-04-27
JP2021532097A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
JP7811843B2 (ja) 微生物生着のための方法および組成物
US11364270B2 (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
US20200121738A1 (en) Methods and compositions relating to isolated and purified microbes
JP2023075323A (ja) マイクロバイオーム関連障害の処置のための方法および組成物
JP7558170B2 (ja) 腸内毒素症を減少させ、微生物叢を復元する方法
AU2016344770B2 (en) Faecalibacterium prausnitzii and Desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
KR20220011683A (ko) 간 장애 치료용 방법 및 조성물
US20210213078A1 (en) Microbial compositions and methods of use
KR20240035473A (ko) 증가된 장의 투과성의 치료용 프로바이오틱 조성물
CN118697770A (zh) 副干酪乳酪杆菌207-27在调节情绪方面的用途
WO2025076184A1 (en) Methods of decreasing dysbiosis and restoring a microbiome
Okombo Use of a probiotic for reduction of gastrointestinal oxalate absorption

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220715

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260127

R150 Certificate of patent or registration of utility model

Ref document number: 7811843

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150